Regulation 33 of SEBO LODR Act 2015

Ebitda Margin CompressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹22.70

prior close

₹22.75

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-0.0% vs market

Pharmaceuticals peers, median of 155sector+0.2%+1.0% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

-0.0

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3+1.3-0.0+0.2+1.0

Next day

+1.6+0.3+1.3-0.4+2.0

+1.1-0.5+1.6-1.1+2.2

+1.3+2.1-0.8+0.7+0.7

-0.7+3.1-3.8+1.3-2.0

+2.6+2.6+0.0+1.4+1.2

+2.6+0.6+2.0+0.3+2.3

15d

-3.1-1.4-1.7-2.3-0.8

-11.9-6.9-5.0-5.1-6.8

-10.8-7.7-3.2-7.9-2.9

-5.3+7.0-12.2+0.8-6.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unjha Formulations Ltd submitted its unaudited financial results for the third quarter and nine months ended December 31, 2025. For Q3, revenue from operations rose to about Rs 443.9 lakh with a net profit of Rs 23.97 lakh, compared to Rs 377.4 lakh revenue and Rs 12.49 lakh profit in the year-ago quarter. For the nine-month period, total income grew modestly to around Rs 1,242 lakh from Rs 1,154 lakh, but profit fell sharply to Rs 81.21 lakh from Rs 144.75 lakh, a drop of roughly 44 percent. The auditor (M/s Jain & Golechha) issued an unqualified limited review report, with no qualifications, emphasis of matter, or concerns flagged. No exceptional items, segment changes, restatements, or related-party issues were disclosed in the filing.

Likely market impact

Despite decent top-line growth, profitability has compressed sharply on a year-to-date basis, pointing to rising input or operating costs squeezing margins. Shareholders should watch whether the company can recover margins in the final quarter.